DETERMINATION IN PLASMA OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR BY INHIBITOR-BINDING ASSAY

被引:5
作者
SHIOYA, H
SHIMOJO, M
KAWAHARA, Y
机构
[1] Product Development Laboratories, Sankyo Co., Ltd., Shinagawa-ku, Tokyo, 140, 2-58
来源
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS | 1991年 / 568卷 / 02期
关键词
D O I
10.1016/0378-4347(91)80168-C
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A method of detemining a new angiotensin-converting enzyme inhibitor (CS-622) and its active metabolite (RS-5139) in plasma by inhibitor-binding assay has been developed using high-performance liquid chromatography. The assay is based on the principle that the amount of inhibitor bound to the enzyme is inversely related to the amount of hippuric acid liberated on hydrolysis from the artificial substrate (hippuryl-L-hystidyl-L-leucine). Plasma was heated at 60-degrees-C for 15 min, to inactivate endogenous enzyme, and preincubated with rabbit-lung angiotensin-converting enzyme at 37-degrees-C for 3 min. The artificial substrate (5.75 mg/ml in pH 8.3 phosphate buffer containing sodium chloride) was added to the resulting solution, and the mixture was incubated for 30 min. The reaction was terminated by the addition of 2 M hydrochloric acid. The hippuric acid liberated on hydrolysis was extracted with ethyl acetate and determined by reversed-phase chromatography using methylparaben as an internal standard. The total concentration of the inhibitor and its metabolite were determined by this method after de-esterification by rat-plasma esterase. The standard curve was obtained by the regression analysis of log concentration against logit response. The within-day and day-to-day precision were satisfactory. The proposed method is simple, rapid and sensitive enough to determine angiotensin-converting enzyme inhibitor in plasma.
引用
收藏
页码:309 / 314
页数:6
相关论文
共 9 条
[1]   ENALAPRIL MALEATE AND A LYSINE ANALOG (MK-521) IN NORMAL VOLUNTEERS - RELATIONSHIP BETWEEN PLASMA DRUG LEVELS AND THE RENIN-ANGIOTENSIN SYSTEM [J].
BIOLLAZ, J ;
SCHELLING, JL ;
COMBES, BJD ;
BRUNNER, DB ;
DESPONDS, G ;
BRUNNER, HR ;
ULM, EH ;
HICHENS, M ;
GOMEZ, HJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 14 (03) :363-368
[2]  
HIKENS M, 1981, LIGAND Q, V4, P43
[3]  
RAKHIT A, 1984, CLIN CHEM, V30, P1237
[4]   PHARMACOKINETICS AND PHARMACODYNAMICS OF PENTOPRIL, A NEW ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR IN HUMANS [J].
RAKHIT, A ;
HURLEY, ME ;
TIPNIS, V ;
COLEMAN, J ;
ROMMEL, A ;
BRUNNER, HR .
JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (03) :156-164
[5]  
REYDELBAX P, 1987, CLIN CHEM, V33, P549
[6]   DETERMINATION OF A NEW ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR (CS-622) AND ITS ACTIVE METABOLITE IN PLASMA AND URINE BY GAS-CHROMATOGRAPHY MASS-SPECTROMETRY USING NEGATIVE-ION CHEMICAL IONIZATION [J].
SHIOYA, H ;
SHIMOJO, M ;
KAWAHARA, Y .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 496 (01) :129-135
[7]   DETERMINATION OF PENTOPRIL, AN ANGIOTENSIN CONVERTING-ENZYME-INHIBITOR, AND ITS ACTIVE METABOLITE IN URINE [J].
TIPNIS, V ;
RAKHIT, A .
JOURNAL OF CHROMATOGRAPHY, 1985, 345 (02) :396-401
[8]  
TOCCO DJ, 1982, DRUG METAB DISPOS, V10, P15
[9]   PHARMACOKINETICS AND PHARMACODYNAMICS OF A NOVEL ORALLY ACTIVE ANGIOTENSIN CONVERTING ENZYME-INHIBITOR (HOE 498) IN HEALTHY-SUBJECTS [J].
WITTE, PU ;
IRMISCH, R ;
HAJDU, P ;
METZGER, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 27 (05) :577-581